Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.
暂无分享,去创建一个
[1] Y. Matsuzawa,et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. , 2002, Circulation journal : official journal of the Japanese Circulation Society.
[2] Y. Liu,et al. Medication for hypercholesterolemia and the risk of nonfatal acute myocardial infarction: case-control study in Japan. , 2002, Circulation journal : official journal of the Japanese Circulation Society.
[3] A. Takeshita,et al. Role of hypertension, dyslipidemia and diabetes mellitus in the development of coronary atherosclerosis in Japan. , 2001, Japanese circulation journal.
[4] B. Davis,et al. Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.
[5] S. Yamashita,et al. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. , 2001, Japanese circulation journal.
[6] Y. Miyake. Risk Factors for Non-Fatal Acute Myocardial Infarction in Middle-Aged and Older Japanese , 2000 .
[7] Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. , 2000, Journal of atherosclerosis and thrombosis.
[8] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[9] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[10] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[11] Alan C. Wilson,et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension , 1998 .
[12] Y. Friedlander,et al. Risk factors for ischemic stroke: Dubbo Study of the elderly. , 1998, Stroke.
[13] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[14] B. Davis,et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1998, Stroke.
[15] C. Hennekens,et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.
[16] R. Westendorp,et al. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.
[17] N. Yoshiike,et al. A 15.5-year follow-up study of stroke in a Japanese provincial city. The Shibata Study. , 1997, Stroke.
[18] D. Tanné,et al. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. , 1997, Stroke.
[19] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[20] A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group. , 1996, Journal of atherosclerosis and thrombosis.
[21] D. Kromhout. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.
[22] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[23] C. Furberg,et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.
[24] C. Hennekens,et al. An overview of trials of cholesterol lowering and risk of stroke. , 1995, Archives of internal medicine.
[25] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[26] H. Mabuchi,et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.
[27] G. Boysen,et al. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study , 1994, BMJ.
[28] Katsuhiko Yano,et al. Elevated Serum Cholesterol Is a Risk Factor for Both Coronary Heart Disease and Thromboembolic Stroke in Hawaiian Japanese Men: Implications of Shared Risk , 1994, Stroke.
[29] David C. Atkins,et al. Cholesterol Reduction and the Risk for Stroke in Men , 1993, Annals of Internal Medicine.
[30] R Peto,et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.
[31] L. Wilhelmsen,et al. Risk factors for stroke in middle-aged men in Göteborg, Sweden. , 1990, Stroke.
[32] D. Jacobs,et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.
[33] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[34] J. Neaton,et al. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.
[35] Daniel B Hier,et al. Race, sex and occlusive cerebrovascular disease: a review. , 1986, Stroke.
[36] C. E. Becker. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.
[37] H. Kato,et al. Cerebrovascular Diseases in a Fixed Population of 653 Hiroshima and Nagasaki, With Special Reference to Relationship Between Type and Risk Factors , 1984, Stroke.
[38] A. V. Peterson,et al. Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort. , 1984, Journal of chronic diseases.
[39] C. Date,et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. , 1982, Stroke.
[40] The coronary primary prevention trial: design and implementation: the Lipid Research Clinics Program. , 1979, Journal of chronic diseases.
[41] D. Grafnetter,et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. , 1978, British heart journal.
[42] W. Holmes. The Multiple Risk Factor Intervention Trial (MRFIT) , 1977 .
[43] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[44] C. Rimington,et al. Symptomatic porphyria in a case of Felty's syndrome. I. Clinical and routine biochemcial studies. , 1972, Clinical chemistry.